Tocilizumab prescribing criteria for COVID-19 patients.

Al-Qaaneh, Ayman M; Al-Ghamdi, Fuad H

Al-Qaaneh, Ayman M; Al-Ghamdi, Fuad H.

Al-Qaaneh AM; Clinical Pharmacy Services Division, Pharmacy Services Department, Johns Hopkins Aramco Healthcare (JHAH), Dhahran, Saudi Arabia.
Al-Ghamdi FH; Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.

Hum Vaccin Immunother ; 17(4): 1128, 2021 Apr 03.

Article in English | MEDLINE | ID: covidwho-880767

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; COVID-19 Drug Treatment; COVID-19/pathology; Cytokine Release Syndrome/drug therapy; Immunologic Factors/therapeutic use; Humans; Retrospective Studies; SARS-CoV-2/drug effects

Keywords

COVID-19; SARS-CoV-2; Tocilizumab; cytokine storm; interleukin 6; monoclonal antibody

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Cytokine Release Syndrome / COVID-19 / COVID-19 Drug Treatment / Immunologic Factors Type of study: Observational study Limits: Humans Language: English Journal: Hum Vaccin Immunother Year: 2021 Document Type: Article Affiliation country: 21645515.2020.1822137

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google